北京商报讯（记者 丁宁）1月12日晚间，天益医疗（301097）发布公告称，基于对公司未来持续发展的 信心和对公司长期价值的合理判断，为有效维护公司价值和广大投资者权益，促进公司长期稳健发展， 增强投资者信心，在综合考虑公司财务状况、经营状况后，公司拟使用自有资金及银行贷款以集中竞价 方式回购公司部分已发行的人民币普通股（A股）股票，用于实施股权激励或员工持股计划。本次拟回 购的资金总额不低于0.6亿元（含）且不超过1.2亿元（含）。 ...

每经头条（nbdtoutiao）——年产量是传统大田120倍以上，1个人管理1栋楼！实探中国"植物工厂"：水 稻生产期从120天减到60天，没有虫害不用打农药 （记者 王晓波） 每经AI快讯，晓鸣股份1月12日晚间发布公告称，截至2026年1月9日，公司通过回购专用证券账户以集 中竞价交易方式累计回购股份数量约为190万股，占公司总股本的1.0103%，成交的最低价格为11.23元/ 股，成交的最高价格为19.18元/股，支付的总金额为人民币约2199万元。公司本次回购股份总金额已达 回购股份方案中回购总金额下限，且未超过回购总金额上限，回购股份价格未超过回购股份方案中规定 的回购价格上限。 ...

Core Viewpoint - The company has approved a share repurchase plan, reflecting confidence in its long-term business development and recognition of its own value [1] Group 1: Share Repurchase Plan - The company is authorized to repurchase up to 10% of its issued shares, excluding treasury shares, from the open market between January 13, 2026, and December 31, 2026 [1] - The total value of the share repurchase is capped at 200 million Hong Kong dollars [1] - The board believes that the share repurchase will not affect normal operations due to the company's strong financial position and ample cash flow [1] Group 2: Strategic Intent - The repurchased shares will be held as treasury stock, aimed at optimizing the capital structure and providing flexibility for future employee incentives and potential acquisitions [1] - This initiative demonstrates management's confidence in the company's prospects and aims to enhance shareholder returns through improved capital efficiency [1]

Core Viewpoint - The company has approved a share repurchase plan, allowing it to buy back up to 10% of its issued shares, valued at a maximum of 200 million Hong Kong dollars, from January 13, 2026, to December 31, 2026 [1] Group 1: Share Repurchase Plan - The board believes the share repurchase plan reflects the company's recognition of its own value and confidence in long-term business development [1] - The financial condition of the company is stable, with ample cash flow, ensuring that the share repurchase will not affect normal operations [1] - Shares repurchased will be used as treasury stock to optimize capital structure and provide flexibility for future employee incentives and potential acquisitions [1] Group 2: Management Confidence and Shareholder Returns - The initiative demonstrates management's confidence in the company's prospects and aims to enhance shareholder returns by improving capital efficiency [1] - The plan aligns with the overall interests of the company and its shareholders [1]

中炬高新公告称，公司拟以自有资金和/或自筹资金，通过集中竞价交易方式回购股份，用于注销并减 少公司注册资本。回购资金总额不低于3亿元，不超过6亿元，回购价格不超26元/股。按此价格测算， 回购3亿元股份数量为11,538,462股，占总股本1.48%；回购6亿元股份数量为23,076,923股，占总股本 2.96%。回购期限自股东会审议通过之日起不超12个月。股东会将授权董事会及经营层办理相关事宜。 ...

智通财经APP讯，捷利交易宝(08017)发布公告，于2026年1月12日，该公司斥资332.8万港元回购200万 股股份，每股回购价1.65-1.67港元。 ...

Core Viewpoint - China Heartland Fertilizer (01866.HK) has announced a new share repurchase plan, allowing the company to buy back up to 10% of its issued shares, equivalent to a maximum value of HKD 200 million, from January 13, 2026, to December 31, 2026 [1] Summary by Relevant Sections - **Share Repurchase Plan** - The company is authorized to repurchase up to 10% of its issued shares, excluding any treasury shares, with a maximum value of HKD 200 million [1] - **Authorization and Compliance** - The implementation of the share repurchase plan must comply with the authorization granted by shareholders at the annual general meeting on June 20, 2025 [1] - Any shares repurchased after the existing authorization expires will require further approval from shareholders at the 2026 annual general meeting to be valid [1]

南山铝业公告称，公司2026年第一次临时股东会已审议通过回购股份议案，拟以自有资金3亿-6亿元， 按不超7.52元/股的价格，回购39,893,617-79,787,234股用于减少注册资本，实施期限自股东会审议通过 之日起不超12个月。根据规定，债权人自接到通知起30日内、未接到通知者自公告披露日起45日内，可 要求公司清偿债务或提供担保。申报时间为2026年1月13日至2月26日，联系人李盛吉。 ...

Group 1 - The stock price of Maide Medical (688310) closed at 16.13 yuan on January 9, 2026, representing a 5.22% increase from the previous week's price of 15.33 yuan [1] - The highest intraday price recorded on January 5 was 16.32 yuan, while the lowest was 15.34 yuan [1] - The current total market capitalization of Maide Medical is 2.681 billion yuan, ranking 74th out of 78 in the automation equipment sector and 4809th out of 5182 in the A-share market [1] Group 2 - Maide Medical announced the repurchase of 127,283 shares on January 5, 2026, accounting for 0.0766% of the total share capital [2][3] - The repurchase price ranged from 15.69 yuan to 15.80 yuan per share, with a total payment of 2,004,504.07 yuan (excluding transaction fees) [2][3] - The repurchase is based on a plan approved by the shareholders' meeting on December 30, 2025, with funding sourced from either excess raised funds or self-owned funds, aimed at reducing registered capital [2][3]

Core Viewpoint - The company emphasizes its commitment to investor returns through various methods, including cash dividends, investor relations management, information disclosure, and share buybacks, while focusing on enhancing operational efficiency and profitability through innovation and strategic investments [1] Group 1: Investor Returns - The company has implemented continuous dividends for six years since its listing, with a total dividend payout of 788 million yuan, and the dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted actors have increased their holdings in the company three times, with a total investment of approximately 384 million yuan [1] - The company has launched three rounds of share buyback plans, with a cumulative buyback amount of about 249 million yuan as of December 31, 2025 [1] Group 2: Share Buyback and Cancellation - To fulfill commitments regarding the buyback plan and enhance investor returns, the company canceled 1,459,586 shares from its buyback on January 6, 2026 [1] Group 3: Business Strategy and Growth - The company focuses on enhancing value creation capabilities through technological innovation, scenario upgrades, and globalization to improve operational efficiency and profitability [1] - It aims to accelerate investment and acquisition processes to strengthen existing industries and expand business boundaries, thereby reshaping its industrial development pattern and enhancing core competitiveness and investment value [1]